Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
Bangladesh’s Beximco Pharmaceuticals Ltd said on Thursday the Serum Institute of India (SII) had delayed the first supplies of a COVID-19 vaccine for personal sale, instead prioritising government immunisation campaigns.
Beximco is Bangladesh’s exclusive distributor of the Oxford University-AstraZeneca shot that SII, the world’s biggest vaccine maker, is producing in bulk for low- and medium-income nations.
The Bangladeshi firm last week received 5 million of those 30 million doses it had purchased from SII for Bangladesh’s immunisation programme that starts next week.
Beximco had separately ordered 1 million doses available on the private market, with the hope to start promoting it this month.
“However, the company has now been informed by SII that the first instalment (500,000 doses) of this supply will be postponed following a prioritisation on supplying vaccine doses for authorities mass vaccination programmes and WHO-led COVAX initiatives over private pay use,” Beximco said in a regulatory filing.
“It remains unclear how long this delay will last.”
Beximco’s chief operating officer told Reuters last month the firm could buy up to 3 million doses of the vaccine from SII at roughly $8 each for sale on the private sector.
The purchase price is roughly twice the $4 per dose that Beximco had agreed for the government programme.
AstraZeneca was embroiled in a dispute in Europe after it said it would have to cut supplies of its own vaccine there in the first quarter.
